Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 138

Sort by

Sort Order Select

Journal Articles

Vedolizumab for steroid-refractory gastrointestinal acute graft-versus-host disease: A real-world VAST study

Le-Qing Cao, Yi Xia, Song Xue, Na Xu, Jian-Ping Zhang, Yang Cao, Yue-Wen Wang, Ze Tian, Jun Kong, Dao-Xing Deng, Xiaohui Zhang, Xiao-Dong Mo

Blood (2025) 146 (Supplement 1): 7772.

https://doi.org/10.1182/blood-2025-7772

Published: 2025

Journal Articles

Oral iptacopan demonstrates efficacy as salvage therapy for high-risk transplant-associated thrombotic microangiopathy: First real-world experience

Fei Gao, Qi Wen, Jian-Ping Zhang, Yuanyuan Zhang, Na Xu, Yeqian Zhao, Jimin Shi, He Huang, Xiaofan Li, Yang Cao, Weijie Cao, Xiaodong Mo, Yanmin Zhao

Blood (2025) 146 (Supplement 1): 2431.

https://doi.org/10.1182/blood-2025-2431

Published: 2025

Journal Articles

Wstf degradation through nuclear autophagy promotes inflammatory responses in primary myelofibrosis: Implications for XPO1 inhibitor-based therapeutic strategies

Na Xu, Ziyu Wen, Bingyu Lin, Jiayi Li, Xuan Zhou, Xiaoli Liu

Blood (2025) 146 (Supplement 1): 7280.

https://doi.org/10.1182/blood-2025-7280

Published: 2025

Journal Articles

Efficacy and safety of peginterferon alfa-2b for chronic myeloid leukemia and essential thrombocythemia during pregnancy

Ziyu Wen, Xuan Zhou, Bingyu Lin, Qiang WANG, Liping Ma, Huilan Zeng, Zhi Liu, Bolin He, Qing Zhang, Mei Zhong, Xiaoli Liu, Na Xu

Blood (2025) 146 (Supplement 1): 7358.

https://doi.org/10.1182/blood-2025-7358

Published: 2025

Journal Articles

Ferritin change and predictors of anemia response in ruxolitinib-intolerant myelofibrosis patients treated with gecacitinib

Yi Zhang, Hu Zhou, Zhijian Xiao, Minghui Duan, Sujun Gao, Guangsheng He, Hongmei Jing, Junmin Li, Liangming Ma, Huanling Zhu, Chunkang Chang, Xin Du, Mei Hong, Xin Li, Qingchi Liu, Wei WANG, Na Xu, Haiping Yang, Jie Jin

Blood (2025) 146 (Supplement 1): 2029.

https://doi.org/10.1182/blood-2025-2029

Published: 2025

Journal Articles

Efficacy and safety of gecacitinib in thrombocytopenic myelofibrosis patients

Blood (2025) 146 (Supplement 1): 2028.

https://doi.org/10.1182/blood-2025-2028

Published: 2025

Journal Articles

Long-term efficacy and safety of ropeginterferon alfa-2b under its hidat regimen for the treatment of polycythemia vera

Blood (2025) 146 (Supplement 1): 2039.

https://doi.org/10.1182/blood-2025-2039

Published: 2025

Journal Articles

Olverembatinib (HQP1351) demonstrates efficacy vs. best available therapy (BAT) in patients (pts) with tyrosine kinase inhibitor (TKI)-resistant chronic-Phase chronic myeloid leukemia (CML-CP) in a registrational randomized Phase 2 trial: Up to 4-year follow-up including patients without T315I mutations

Blood (2025) 146 (Supplement 1): 3788.

https://doi.org/10.1182/blood-2025-3788

Published: 2025

Journal Articles

Treatment-free remission outcomes in pediatric chronic myeloid leukemia: Second-generation TKIs vs. Imatinib–a real-world multicenter study from China

HUIFANG ZHAO, Yu Zhu, Na Xu, QINGSHU ZENG, Shuxia Guo, Li xin Liang, Bingcheng LIU, Weiming Li, Qian Jiang, Yanli Zhang

Blood (2025) 146 (Supplement 1): 3786.

https://doi.org/10.1182/blood-2025-3786

Published: 2025

Journal Articles

Updated efficacy and safety of olverembatinib (HQP1351) as second-line therapy in patients (pts) with chronic Phase-chronic myeloid leukemia (CP-CML)

Li Weiming, Yanli Zhang, Huangling Zhu, Yunfan Yang, Na Xu, Bingcheng LIU, Fang Cheng, Zi Chen, Wei Chu, Yifan Zhai, Yu Hu

Blood (2025) 146 (Supplement 1): 3782.

https://doi.org/10.1182/blood-2025-3782

Published: 2025

Journal Articles

Flumatinib versus nilotinib as first-line therapy for chronic myeloid leukemia in chronic Phase: A propensity score-matched cohort study

Ziyu Wen, Bingyu Lin, Qiang WANG, Xuan Zhou, Xiaoli Liu, Xin Du, Na Xu

Blood (2025) 146 (Supplement 1): 3776.

https://doi.org/10.1182/blood-2025-3776

Published: 2025

Journal Articles

Human intestinal acute graft-versus-host disease is governed by a subset of transition-like tissue-resident memory CD8+ T cells

Yiming Sun, Yutong Xue, Ruoyang Shao, Xinyu Liu, Chenyuyao Song, Zhiping Fan, Ren Lin, Na Xu, Qifa Liu, Hua Jin

Blood (2025) 146 (Supplement 1): 2453.

https://doi.org/10.1182/blood-2025-2453

Published: 2025

Journal Articles

Sorafenib enhances anti-leukemia effect via promoting macrophage-NK cell immune crosstalk in FLT3-ITD+ AML patients receiving allo-HSCT

Ruoyang Shao, Peiru Chi, Yuxin Bai, Fang Dai, Tian Zhang, Zhonghui Jiang, Xi Xu, Xiaofeng Yang, Kejing Li, Guo Qiu, Yueyang Zhong, Na Xu, Fen Huang, Zhiping Fan, Ren Lin, Hua Jin, Jing Sun, Qifa Liu, Xuan Li

Blood (2025) 146 (Supplement 1): 2308.

https://doi.org/10.1182/blood-2025-2308

Published: 2025

Journal Articles

Long-term treatment continuation of gecacitinib in myelofibrosis patients after ruxolitinib failure

Blood (2025) 146 (Supplement 1): 5584.

https://doi.org/10.1182/blood-2025-5584

Published: 2025

Journal Articles

Conversion from calcineurin inhibitor to ruxolitinib as GVHD prophylaxis during patients with transplant-associated thrombotic microangiopathy

Yan Zhang, Hanyin Liang, Na Xu

Blood (2025) 146 (Supplement 1): 7718.

https://doi.org/10.1182/blood-2025-7718

Published: 2025

Journal Articles

Sorafenib Combined with Chemotherapy and Donor Lymphocyte Infusion for Patients with FLT3 Wild-Type Acute Leukemia Relapsing after Allo-HSCT

Tian Zhang, Peiru Chi, Zhiping Fan, Na Xu, Hui Xu, Fen Huang, Ren Lin, Zhixiang Wang, Hui Liu, Xueying Ou, Ke Zhao, Ling Jiang, Jing Sun, Qifa Liu, Li Xuan

Blood (2024) 144 (Supplement 1): 7385.

https://doi.org/10.1182/blood-2024-203334

Published: 2024

Journal Articles

Variables Associated with Outcomes in Patients with Chronic Neutrophilic Leukemia with CSF3R T618I : A Multi-Centre Retrospective Study

Blood (2024) 144 (Supplement 1): 1793.

https://doi.org/10.1182/blood-2024-207591

Published: 2024

Journal Articles

Intensified Conditioning Containing Decitabine Versus Standard Myeloablative Conditioning for Adult Patients with KMT2A-Rearranged Leukemia: A Multicenter Retrospective Study

Zhongli Hu, Hai He, Shiqi Liu, Ying Dong, Zhiping Fan, Yiqing Li, Fen Huang, Na Xu, Can Liu, Yunxin Zeng, Ping Zhu, Ren Lin, Hua Jin, Xiong Zhang, Ruijuan Sun, Qifa Liu, Li Xuan

Blood (2024) 144 (Supplement 1): 2123.

https://doi.org/10.1182/blood-2024-202822

Published: 2024

Journal Articles

Clinical Characteristics and Risk Factors of Chronic Kidney Disease Among Patients with Myeloproliferative Neoplasms

Zicheng Gao, Xuan Zhou, Qiang Wang, Dan Xu, Xiaoli Liu, Na Xu, Qifa Liu

Blood (2024) 144 (Supplement 1): 6643.

https://doi.org/10.1182/blood-2024-207289

Published: 2024

Journal Articles

Safety and Efficacy of Luspatercept for the Treatment of Refractory Anemia in Patients with Myelofibrosis

Ziyu Wen, Xuan Zhou, Bingyu Lin, Xiaoli Liu, Qiang Wang, Na Xu

Blood (2024) 144 (Supplement 1): 6639.

https://doi.org/10.1182/blood-2024-205673

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Vedolizumab for steroid-refractory gastrointestinal acute graft-versus-host disease: A real-world VAST study

Oral iptacopan demonstrates efficacy as salvage therapy for high-risk transplant-associated thrombotic microangiopathy: First real-world experience

Wstf degradation through nuclear autophagy promotes inflammatory responses in primary myelofibrosis: Implications for XPO1 inhibitor-based therapeutic strategies

Efficacy and safety of peginterferon alfa-2b for chronic myeloid leukemia and essential thrombocythemia during pregnancy

Ferritin change and predictors of anemia response in ruxolitinib-intolerant myelofibrosis patients treated with gecacitinib

Efficacy and safety of gecacitinib in thrombocytopenic myelofibrosis patients

Long-term efficacy and safety of ropeginterferon alfa-2b under its hidat regimen for the treatment of polycythemia vera

Treatment-free remission outcomes in pediatric chronic myeloid leukemia: Second-generation TKIs vs. Imatinib–a real-world multicenter study from China

Updated efficacy and safety of olverembatinib (HQP1351) as second-line therapy in patients (pts) with chronic Phase-chronic myeloid leukemia (CP-CML)

Flumatinib versus nilotinib as first-line therapy for chronic myeloid leukemia in chronic Phase: A propensity score-matched cohort study

Human intestinal acute graft-versus-host disease is governed by a subset of transition-like tissue-resident memory CD8+ T cells

Sorafenib enhances anti-leukemia effect via promoting macrophage-NK cell immune crosstalk in FLT3-ITD+ AML patients receiving allo-HSCT

Long-term treatment continuation of gecacitinib in myelofibrosis patients after ruxolitinib failure

Conversion from calcineurin inhibitor to ruxolitinib as GVHD prophylaxis during patients with transplant-associated thrombotic microangiopathy

Sorafenib Combined with Chemotherapy and Donor Lymphocyte Infusion for Patients with FLT3 Wild-Type Acute Leukemia Relapsing after Allo-HSCT

Variables Associated with Outcomes in Patients with Chronic Neutrophilic Leukemia with CSF3R T618I : A Multi-Centre Retrospective Study

Intensified Conditioning Containing Decitabine Versus Standard Myeloablative Conditioning for Adult Patients with KMT2A-Rearranged Leukemia: A Multicenter Retrospective Study

Clinical Characteristics and Risk Factors of Chronic Kidney Disease Among Patients with Myeloproliferative Neoplasms

Safety and Efficacy of Luspatercept for the Treatment of Refractory Anemia in Patients with Myelofibrosis

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only